LIMN Liminatus Pharma, Inc.

Nasdaq liminatuspharma.com


$ 1.14 $ -0.08 (-6.5 %)    

Friday, 17-Oct-2025 19:34:22 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 1.15
$ 1.22
$ 1.11 x 195
$ 1.17 x 20
$ 1.11 - $ 1.24
$ 1.11 - $ 33.66
384,526
na
26.8M
$ -1.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-04-2025 06-30-2025 10-Q
2 05-31-2025 03-31-2025 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. has entered into a Memorandum of Understanding (MOU) to form a research and development consortium with ...

 us-stocks-likely-to-open-higher-sp-500-sees-average-gain-of-61-in-2nd-half-expert-says

U.S. futures rose on Wednesday after a mixed close on Tuesday. Futures of major benchmark indices were trading slightly higher.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION